XBiotech's Competitors, Revenue, Number of Employees, Funding and Acquisitions

XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer... Read more

Based on data from XBiotech's latest SEC filings

Annual Revenue

Based on data from XBiotech's latest SEC filings

Employees

John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating

76/100

OVERVIEW

Founded:

2005

Headquarters:

AustinTexas

Status:

PublicIndependent Company of NASDAQXBIT

Industry Sector:

Biotechnology

SIC Code:

2834NAICS listing »

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is InflaRx a competitor of XBiotech?

I don't know

Trending News for XBiotech and XBiotech's Competitors

October 16, 2019

Seeking Alpha

Aclaris up 12% on Arkin stake

See more »

October 16, 2019

Seeking Alpha

The Medicines Company A Buy On Inclisiran Data, With Caveats

See more »

October 17, 2019

HealthCare Dive

Novartis takes step back from marketing Pear prescription digital therapeutics

The move at Sandoz comes as recently minted CEO Richard Saynor refocuses the Novartis unit.... See more »
Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

XOMA is perceived as one of XBiotech's biggest rivals. XOMA was founded in 1981 in Emeryville, California. XOMA is in the Pharmaceuticals field. XOMA generates $29.3M less revenue than XBiotech.

Aclaris is XBiotech's #2 rival. Aclaris is a Public company that was founded in 2012 in Wayne, Pennsylvania. Aclaris competes in the Pharmaceuticals field. Compared to XBiotech, Aclaris has 63 more employees.

Elcelyx Therapeutics is one of XBiotech's top competitors. Elcelyx Therapeutics's headquarters is in San Diego, California, and was founded in 2009. Elcelyx Therapeutics operates in the Health Care Services industry. Elcelyx Therapeutics generates 10% of XBiotech's revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

John Simard

Chairman & CEO

- -
106
$76M
$41M
1

James R. Neal

CEO

84/100
80
$20M
$11.7M
2

Neal Walker

President & CEO

90/100
169
$167M
$27.4M
3

Alain D. Baron

President & CEO

79/100
40
$93.3M
$4.4M
4

Niels C. Riedemann

Founder & CEO

86/100
17
$89M
$5M
5

Cedric Francois

President & CEO

71/100
87
$163.3M
6

Thomas Lingelbach

President & CEO

86/100
3
$148.9M
$ < 1M
7

Joanne Kotz

President & CEO

82/100
20
$50M
$ < 1M
8

Mark Timney

CEO

86/100
410
$96M
$ < 1M
9

Alfred Altomari

Chairman & CEO

85/100
19
$157.5M
$10.7M
10

Simon Sturge

CEO

83/100
170
$199.5M
$6.5M
The top 10 competitors in XBiotech's competitive set are XOMA, Aclaris, Elcelyx Therapeutics, InflaRx, Apellis, Valneva, Jnana, The Medicines Company, Agile Therapeutics and Kymab. Together they have raised over 1.2B between their estimated 1.1K employees. XBiotech has 106 employees and is ranked 4th among it's top 10 competitors. The top 10 competitors average 101.

Quarterly and Annual Revenue

Coming soon for XBiotech!

Annual Revenue

$41M

XBiotech's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 10.5M.

Acquisitions

No recent acquisitions found related to XBiotech

XBiotech Funding History

Since XBiotech was founded in 2005, it has participated in 1 round of funding. In total XBiotech has raised $76.0M. XBiotech's funding round was on Apr 2015 for a total of $76.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2015
$76M
-

Total Funding: $76M

Since XBiotech was founded in 2005, it has participated in 1 round of funding. In total XBiotech has raised $76.0M. XBiotech's funding round was on Apr 2015 for a total of $76.0M

Investments

No recent investments found related to XBiotech

XBiotech News

September 20, 2019MarketScreener

XBiotech Announces Granting of Canadian Patent for Treatment of Dermatological Pathologies

(marketscreener.com) AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) a... See more »
September 9, 2019MarketScreener

Statement of changes in beneficial ownership of securities

(marketscreener.com) SEC Form 4 FORM 4 Check this box if no longer subject to Section 16. Form 4 or F... See more »
September 9, 2019MarketScreener

Initial filing by director officer or owner of more than ten percent.

(marketscreener.com) SEC Form 3 ...http://www.marketscreener.com/news/XBiotech-Initial-filing-by-dire... See more »
July 10, 2019Benzinga

XBiotech Adds Dr. Peter Libby, Renowned Cardiologist and Research Pioneer in Inflammation and Cardiovascular Disease, to its Corporate Board

AUSTIN, Texas, July 10, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that Pet... See more »
June 26, 2019FinanzNachrichten

XBiotech Wins "Commercial Real Estate Award for Industrial Development" for its Headquarters in Austin, Texas

AUSTIN, Texas, June 26, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it... See more »
June 12, 20194-traders

An amendment to the SC 13G filing

(marketscreener.com) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE... See more »
June 11, 2019FinanzNachrichten

XBiotech Added to Russell 3000 Index

AUSTIN, Texas, June 11, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that th... See more »

XBiotech Press Releases

September 4, 2017BriefingWire

Restenosis-Pipeline Review, H2 2017

ReportsWeb.com published "Restenosis Market" from its database. The report covers the market landscap... See more »
May 16, 2017Blackbird

Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. - XBIT

See more »
November 10, 2016GlobeNewswire

XBiotech to Provide Third Quarter 2016 Business Update on November 15

See more »
July 25, 2016PR Newswire

Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of XBiotech, Inc. - XBIT

NEW YORK, July 26, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation ... See more »
March 11, 2016GlobalNewswire

XBiotech Enrolls Final Patient in Phase I Portion of Clinical Study of Novel True Human Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus

See more »
March 11, 2016GlobalNewswire

European Medicines Agency Grants Eligibility for Submission of XBiotech's Marketing Authorization Application (MAA)

See more »
February 18, 2016GlobeNewswire

XBiotech to Present at 4th Annual Sachs Cancer BioPartnering & Investment Forum

See more »

Social Statistics

Headquarters

5217 Winnebago Lane

Austin, Texas78744

512-386-2900

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer. XBiotech was founded in 2005. XBiotech's headquarters is located in Austin, Texas, USA 78744. It has raised 76.0M in 1 round. The...

CEO

XBiotech's Chairman & CEO, John Simard, currently has an approval rating of 76%. XBiotech's primary competitors are XOMA, Aclaris & Elcelyx Therapeutics.

Website

xbiotech.com

Frequently Asked Questions about XBiotech

  1. When was XBiotech founded?

    XBiotech was founded in 2005

  2. Who is XBiotech's CEO?

    XBiotech's CEO is John Simard

  3. How much revenue does XBiotech generate?

    XBiotech generates $41M in revenue

  4. How much funding does XBiotech have?

    XBiotech has historically raised $76M in funding

  1. Where is XBiotech's headquarters?

    XBiotech's headquarters is in Austin Texas, USA

  2. How many employees does XBiotech have?

    XBiotech has 106 employees

  3. What sector does XBiotech operate in?

    XBiotech is in Biotechnology

  4. Who are XBiotech's competitors?

    XBiotech's top competitors are XOMA, Aclaris, Elcelyx Therapeutics
Stay up-to-date with the latest news on XBiotech

© 2019 Owler, Inc.